Join our daily newsletter At The Bell to receive exclusive market insights
- CEO of Resonance Health (RHT) Alison Laws has tendered her resignation due to unplanned personal family obligations
- Alison has been CEO since February 2018 and during this time the company achieved growth in sales volumes, profitability, revenue and cash at the bank
- Her last day with the Resonance will likely be in early July, however the company will confirm this in due course
- Effective immediately, director Mitchell Wells has been appointed executive director
- Mitchell has been a director since February 2018 has worked closely with Alison to provide commercial advisory services
- Shares in Resonance are down 5.13 per cent and are trading at 18.5 cents
CEO of Resonance Health (RHT) Alison Laws has tendered her resignation due to unplanned personal family obligations.
Alison has been CEO since February 2018 and during this time the company has achieved growth in sales volumes, profitability, revenue and cash at the bank.
Her last day with the Resonance will likely be in early July, however the company will confirm this in due course.
“It has been an immense privilege to lead Resonance Health. There are only a handful of Australian med-tech companies that can boast several regulatory cleared products including new AI-based scaleable products, profitability and an exciting growth-focused research and development pipeline,” Ms Laws said.
“Whilst personal circumstances dictate that I step down from the CEO position, I look forward to continuing to work with Mitch Wells, Nick Allan and the whole team in an advisory capacity,” she added.
Effective immediately, director Mitchell Wells has been appointed Executive Director.
Mitchell has been a director since February 2018 has worked closely with Alison to provide commercial advisory services.
Further to the announcement made on April 8, Nick Allan has begun in the roles of chief financial officer and company secretary.
Resonance has also successfully applied for and obtained regulatory clearances for new medical devices using artificial intelligence (AI).
These devices have positioned Resonance for growth, with the company developing a global sales and marketing strategy.
Shares in Resonance are down 5.13 per cent and are trading at 18.5 cents at 11:36 am AEST.
